WAGNER PAULA
Artículos
Título:
The chemotherapeutic effect of SR9009, a REV-ERB agonist, on the human glioblastoma T98G cells
Autor/es:
PAULA M. WAGNER; NATALIA M MONJES; MARIO E. GUIDO
Revista:
ASN Neuro
Editorial:
Sage journals
Referencias:
Año: 2019
ISSN:
1759-0914
Resumen:
lioblastoma multiforme (GBM) is the most aggressive brain tumor and human T98G cells constitute a useful GBM model to evaluate chemotherapeutic agents. Modern life (shiftwork, jetlag, etc.) may cause circadian disorganization promoting higher cancer risk and metabolic disorders. Although little is known about the tumor-intrinsic circadian clock function, pharmacological modulation of circadian components may offer selective anticancer strategies. REV-ERBs are heme-binding circadian clock components acting as repressors of processes involved in tumorigenesis such as metabolism, proliferation and inflammation. A synthetic pyrrole derivative (SR9009) that acts as REV-ERBs specific agonists exhibits potent in vivo activity on metabolism and tumor cell viability. Here we investigated SR9009 effects on T98G cell viability, differential chemotherapy time responses and underlying metabolic processes (reactive oxygen species: ROS and lipid droplets: LD) and compared it with the proteasome inhi